Perspectives

1:05
Anas Younes: two practice-changing abstracts at ASH 2018
Anas Younes
2:43
MRD highlights in myeloma from ASH 2018
Ola Landgren
1:50
Cellular therapies for NHL: current challenges and perspectives
Ian Flinn
1:52
ERIC’s first International Meeting and plans for the future
Paolo Ghia
3:18
Opinion on MRD in CLL: routine use or clinical trials?
Kanti Rai
0:51
An update on ERIC initiatives
Paolo Ghia
1:00
European Research Initiative on CLL (ERIC) International Meetings
Kostas Stamatopoulos
1:49
The future of CLL: managing new toxicities and improved categorization
Daniel Catovsky
2:34
MRD in CLL: utility from trials to individuals
John Seymour
1:11
Let me introduce you to ERIC: the European Research Initiative on CLL
Paolo Ghia
1:25
A perspective on MRD in CLL: treatment efficacy, early relapse detection & more
Eva Kimby
1:04
The first ERIC International Meeting: advancing the CLL field
Emili Montserrat
1:09
Novel ventoclax combinations for CLL
Eva Kimby
1:16
Thoughts on the use of MRD in CLL
Daniel Catovsky
2:05
CLL progress: a brief history
Emili Montserrat
3:09
Frontline transplant-ineligible MM treatment
Kwee Yong
The content of VJHemOnc is intended for healthcare professionals